Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing a novel approach to hard-to-treat cancers through the development of Polynucleotide Kinase Phosphatase (PNKP) inhibitors, a new class of DNA Damage Response (DDR) therapies designed to disrupt cancer cells' ability to repair DNA damage. The company recently achieved a key manufacturing milestone with the successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010.
Cancers frequently exhibit defective repair of damaged DNA, leading to the accumulation of mutations that can give rise to unchecked growth, evasion of the immune system, and the capacity to spread. Conventional DNA damaging therapies, such as radiation treatment or some chemotherapies, can overwhelm a cancer's limited repair capacity resulting in cancer cell death. However, some cancers retain sufficient DNA repair capacity to resist these treatments at doses patients can tolerate. Onco-Innovations is positioning itself within this rapidly evolving area of oncology by targeting PNKP, which plays a critical role in repairing damaged DNA.
The company recently signed a Letter of Intent with Nanosoft Polymers, expected to support polymer development, drug delivery optimization, and formulation work for the ONC010 program. This partnership aims to enhance the delivery and efficacy of the PNKP inhibitor, potentially improving outcomes for patients with cancers that are resistant to conventional therapies. The kilogram-scale production milestone is a significant step toward clinical development and eventual commercialization of ONC010.
For more information on the latest news and updates relating to ONNVF, visit the company's newsroom at ibn.fm/ONNVF.
